# US 2003/0223994 A1 · MHC-peptide complex binding ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223994 A1
- Document ID: US20030223994A1
- Status: Published application
- Kind: A1
- Application number: 10/371,942
- Filed: 2003-02-20
- Published: 2003-12-04
- Earliest claimed: 2002-02-20
- Inventors: Henricus Renerus Jacobus Mattheus Hoogenboom; Yoram Reiter
- Web page: https://patentgrep.com/patent/US20030223994A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands.

## Claims

### Claim 1

A protein comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the protein binds a complex comprising an MHC and a peptide, does not substantially bind the MHC in the absence of the bound peptide, and does not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the protein binds an epitope on the complex comprising a moiety of the peptide and a moiety of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT.

### Claim 3 (depends on 1)

The protein of claim 1, wherein the peptide fragment comprises hTERT-derived peptide T540 (ILAKFLHWL; SEQ ID NO:5) or T865 (RLVDDFLLV; SEQ ID NO:6).

### Claim 4 (depends on 1)

The protein of claim 1, wherein the peptide fragment comprises gp100-derived peptide G9-209 (IMDQVPFSV; SEQ ID NO:1), G9-280 (YLEPGPVTV; SEQ ID NO:2), or G9-154 (KTWGQYWQV; SEQ ID NO:3).

### Claim 5 (depends on 1)

The protein of claim 1, wherein the peptide fragment comprises MUC1-derived D6 peptide (LLLTVLTVV; SEQ ID NO:4).

### Claim 6 (depends on 1)

The protein of claim 1, wherein the peptide fragment comprises TAX-derived peptide LLFGYPVYV (SEQ ID NO:121).

### Claim 7 (depends on 1)

The protein of claim 1 wherein the protein is attached to a cell.

### Claim 8 (depends on 1)

The protein of claim 1 further comprising an effector domain.

### Claim 9 (depends on 8)

The protein of claim 8, wherein the effector domain comprises an Fe domain.

### Claim 10 (depends on 8)

The protein of claim 8, wherein the effector domain comprises a label or cytotoxin or component thereof.

### Claim 11 (depends on 1)

The protein of claim 1, wherein the VH and VL domains are components of the same polypeptide chain.

### Claim 12 (depends on 1)

The protein of claim 1, wherein the VH and VL domains are components of different polypeptide chains.

### Claim 13 (depends on 1)

The protein of claim 1, wherein the association constant for binding of the protein to the complex is at least 107 M−1.

### Claim 14 (depends on 2)

The protein of claim 2, wherein one of the variable regions comprises a CDR that is at least 80% identical to a CDR of 4A9, 4G9, 4C2, 4B4, 3H2, 3G3, 3A12, 3F5, or 3B1.

### Claim 15 (depends on 2)

The protein of claim 2 wherein one of the variable regions comprises a CDR that is at least 80% identical to a CDR of 1A11, 1A7, 1A9, 1C8, 1D7, 1G2, 2B2, 2C5, 2D1, 2F1, G2D12, G3F12, G3F3, or G3G4.

### Claim 16 (depends on 2)

The protein of claim 2 wherein one of the variable regions comprises a CDR that is at least 80% identical to a CDR of M3A1 or M3B8.

### Claim 17 (depends on 2)

The protein of claim 2 wherein one of the variable regions comprises a CDR that is at least 80% identical to a CDR of T3E3, T3F1, or T3F2.

### Claim 18 (depends on 2)

The protein of claim 2 wherein the protein binds an epitope that overlaps, is adjacent to, or is substantially identical to an epitope bound by 4A9, 4G9, 4C2, 4B4, 3H2, 3G3, 3A12, 3F5, or 3B1.

### Claim 19 (depends on 2)

The protein of claim 2 wherein the protein binds an epitope that overlaps, is adjacent to, or is substantially identical to an epitope bound by 1A11, 1A7, 1A9, 1C8, 1D7, 1G2, 2B2, 2C5, 2D1, 2F1, G2D12, G3F12, G3F3, or G3G4.

### Claim 20 (depends on 2)

The protein of claim 2 wherein the protein binds an epitope that overlaps, is adjacent to, or is substantially identical to an epitope bound by M3A1 or M3B8.

### Claim 21 (depends on 2)

The protein of claim 2 wherein the protein binds an epitope that overlaps, is adjacent to, or is substantially identical to an epitope bound by T3E3, T3F1, or T3F2.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising the protein of claim 1; and a pharmaceutical carrier.

### Claim 23 (depends on 22)

The composition of claim 22 in which the protein further comprises a cytotoxin.

### Claim 24 (depends on 22)

The composition of claim 22 in which the protein further comprises a label.

### Claim 25

A cytotoxic T cell that comprises one or more nucleic acids for expressing an immunoglobulin that binds a complex comprising an MHC and a peptide, does not substantially bind the MHC in the absence of the bound peptide, and does not substantially bind the peptide in the absence of the MHC.

### Claim 26 (depends on 25)

The cytotoxic T cell of claim 25, wherein the immunoglobulin is expressed at the cell surface.

### Claim 27

An isolated nucleic acid comprising a first segment that encodes an immunoglobulin variable domain, wherein a protein that comprises the immunoglobulin variable domain and a second immunoglobulin variable domain binds to an MHC-peptide complex, does not substantially bind the MHC in the absence of the bound peptide, and does not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT.

### Claim 28 (depends on 27)

The nucleic acid of claim 27, further comprising a second segment that encodes the second immunoglobulin variable domain.

### Claim 29 (depends on 27)

The nucleic acid of claim 27, wherein the immunoglobulin variable domain comprises a CDR that has no more than 3 substitutions, insertions, or deletions relative to the CDR of a variable region of 4A9, 4G9, 4C2, 4B4, 3H2, 3G3, 3A12, 3F5, or 3B1.

### Claim 30 (depends on 27)

The nucleic acid of claim 27, wherein the immunoglobulin variable domain comprises a CDR that has no more than 3 substitutions, insertions, or deletions relative to the CDR of a variable region of 1A11, 1A7, 1A9, 1C8, 1D7, 1G2, 2B2, 2C5, 2D1, 2F1, G2D12, G3F12, G3F3, or G3G4.

### Claim 31 (depends on 27)

The nucleic acid of claim 27, wherein the immunoglobulin variable domain comprises a CDR that has no more than 3 substitutions, insertions, or deletions relative to the CDR of a variable region of M3A1 or M3B8.

### Claim 32 (depends on 27)

The nucleic acid of claim 27, wherein the immunoglobulin variable domain comprises a CDR that has no more than 3 substitutions, insertions, or deletions relative to the CDR of a variable region of T3E3, T3F1, or T3F2.

### Claim 33

A host cell comprising heterologous nucleic acid sequences that encode a protein comprising an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain, wherein the protein binds to an MHC-peptide complex if the peptide is present in the complex, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT.

### Claim 34

A transgenic animal whose genome includes heterologous nucleic acid sequences that encode a protein comprising an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain, wherein the protein binds to an MHC-peptide complex if the peptide is present in the complex, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT.

### Claim 35

A method comprising:
providing a protein library that comprises proteins, each protein comprising a immunoglobulin variable domain from a subject with a preselected MHC allele;
optionally selecting an MHC complex known to comprise the same allele as the preselected allele;
contacting the library to an MHC-peptide complex, wherein the MHC component of the complex is the same allele as the given preselected MHC allele; and
isolating a member of the library that specifically binds the MHC-peptide complex.

### Claim 36 (depends on 35)

The method of claim 35 wherein the isolated member binds the complex with an association constant of at least 107 M−1.

### Claim 37

A method comprising:
contacting members of a protein library to a single-chain MHC-peptide complex; and;
identifying one or more members that bind to the single-chain MHC-peptide complex, do not substantially bind the MHC in the absence of the peptide, and do not substantially bind the peptide in the absence of the MHC.

### Claim 38

A method comprising:
contacting a protein library to a first mixture of MHC-peptide complexes;
isolating a plurality of members of the library, wherein each isolated member of the plurality displays an antigen binding domain that binds to an MHC-peptide complex and the epitope recognized by the antigen binding domain comprises a moiety of the MHC and a moiety of the peptide; and
identifying members of the plurality that do not substantially bind to a second mixture of MHC-peptide complexes.

### Claim 39 (depends on 36)

The method of claim 36, wherein the peptide is a peptide fragment of MUC1, hTERT, TAX, or gp100.

### Claim 40 (depends on 38)

The method of claim 38, further comprising formulating the antigen binding domain of the isolated member as a pharmaceutical composition.

### Claim 41 (depends on 40)

The method of claim 40, further comprising administering the composition to a subject.

### Claim 42

A method comprising:
providing a first nucleic acid segment encoding a heavy chain variable region and a second nucleic acid segment encoding a light chain variable region, wherein the heavy chain variable region and the light chain variable region form an antigen binding protein that binds an MHC-target peptide complex if the target peptide is present;
introducing said first and second nucleic acid segments into a cytotoxic cell; and
maintaining the cytotoxic cell under conditions that allow expression and assembly of said antigen-binding protein.

### Claim 43 (depends on 1)

A method of ablating or killing a target cell that displays a peptide on a surface MHC molecule, the method comprising:
contacting the target cell with the protein of claim 1, the protein specifically recognizing the displayed peptide on the surface MHC molecule of the target cell, and
ablating or killing the target cell.

### Claim 44 (depends on 43)

The method of claim 43, wherein the protein further comprises a cytotoxic agent.

### Claim 45 (depends on 43)

The method of claim 43, wherein the protein is attached to an effector cell.

### Claim 46 (depends on 22)

A method of treating or preventing a cancerous disorder in a subject, the method comprising:
administering to the subject the pharmaceutical composition of claim 22 in an amount effective to treat or prevent the disorder.

### Claim 47 (depends on 1)

A method for detecting an MHC-peptide complex in a sample, the method comprising:
contacting the sample with the protein of claim 1; and
detecting binding of the protein and the sample, wherein detection of binding indicates presence of the MHC-peptide complex in the sample.

### Claim 48 (depends on 47)

The method of claim 47, wherein the sample is contained within a subject.

### Claim 49

A method comprising:
providing a first nucleic acid segment encoding a heavy chain variable region and a second nucleic acid segment encoding a light chain variable region, wherein the heavy chain variable region and the light chain variable region form an antigen binding protein that binds an MHC-target peptide complex if the target peptide is present and the target peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT;
introducing said first and second nucleic acid segments into a host cell; and
maintaining the host cell under conditions that allow expression and assembly of said antigen-binding protein.
